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OBJECTIVE — To determine the impact of islet transplantation (ITx) on hypoglycemia
awareness in patients with unstable type 1 diabetes and its relation to islet function.
RESEARCH DESIGN AND METHODS — A total of 31 ITx recipients were studied.
Hypoglycemia unawareness was assessed using the Clarke hypoglycemic score (0  no hypo-
glycemia; 4  hypoglycemia unawareness). Subjects were grouped based on graft function:
off-insulin(n8),graftdysfunction(on-insulinandstimulatedC-peptide0.3ng/ml,n13),
andgraftfailure(stimulatedC-peptide0.3ng/ml,n10,evaluated11.514.5monthsafter
graft failure).
RESULTS — The hypoglycemia score improved after ITx when compared with baseline val-
ues (before vs. after: 5.29  1.51 vs. 1.35  1.92, P  0.001). This result was sustained even
after patient stratiﬁcation based on islet function (pre vs. post off-insulin: 5.63  2.00 vs. no
hypoglycemia reported; graft dysfunction: 5.31  1.49 vs. 1.15  1.63, P  0.001; and graft
failure: 5.00  1.16 vs. 2.70  2.26, P  0.014).
CONCLUSIONS — The improved metabolic control achieved with ITx can restore hypo-
glycemia awareness in patients with type 1 diabetes, persisting even after islet graft failure.
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O
ccurrence of hypoglycemia is the
major limitation of intensive con-
trol aimed at A1C normalization in
patients with type 1 diabetes. Frequent
hypoglycemic episodes are particularly
common in subjects with unstable type 1
diabetes and can lead to hypoglycemia
unawareness. Although islet transplanta-
tion (ITx) prevents severe hypoglycemia
(1) and restores some counterregulatory
hormone secretion (2), data showing its
effects on restitution of hypoglycemia
awareness are not conclusive (2,3).
The aim of this study was to deter-
mine if the optimal metabolic control
achievedbyITxcanrestorehypoglycemia
awareness and whether or not these ef-
fects persist after islet graft failure.
RESEARCH DESIGN AND
METHODS— A retrospective cohort
study was conducted on 31 type 1 dia-
betic recipients of ITx (ITx alone, n  25;
islet after kidney, n  6) between 2001
and 2007. Procedures were performed as
described (1) under protocols approved
by the University of Miami Health Re-
search Ethics Board, and informed con-
sent was obtained from each subject.
Hypoglycemia unawareness was as-
sessed using the Clarke hypoglycemic
score (minimum  0; maximum  7; no
hypoglycemia  0; hypoglycemia un-
awareness 4) (4) twice, including pre-
ITx and at the most recent follow-up
(47.2  21.3 months after ﬁrst ITx). Sub-
jects were grouped based on graft func-
tion:off-insulin(n8),graftdysfunction
(restarted insulin and stimulated C-
peptide 0.3 ng/ml, n  13), and graft
failure (stimulated C-peptide 0.3 ng/
ml; n  10, evaluated 11.5  14.5
months after graft failure).
Plasma glucose (hexokinase method)
andC-peptide(doubleantibodyradioim-
munoassay) were measured during a
mixed-meal test. A1C (high-performance
liquid chromatography [HPLC]; Bio-Rad,
Richmond, CA; normal values: 4.2–
6.1%) was determined before ITx and at
the most recent follow-up.
Proportions were compared with the

2 test. The paired t test was used to com-
parevariablespre-andpost-ITx,andone-
way ANOVA was used to compare the
post-ITx hypoglycemic score among
groups. P values (two-tailed) 0.05 and
0.016 (Bonferroni’s correction for dif-
ferences among subgroups) were consid-
ered signiﬁcant.
RESULTS— Patient age at baseline
was 43.8  8.7 years, and diabetes dura-
tionwas29.311.8years.Subjectswere
white, and 13 (42%) were males. A total
of 13 subjects (42%) had hypertension,
and 11 (35%) had dyslipidemia. Diabetes
complications at baseline included reti-
nopathy (71%; n  22; 14 proliferative),
neuropathy(45%;n14;4autonomic,7
peripheral,and3both),andnephropathy
(29%; n  9; 3 microalbuminuria and 6
with a kidney transplant 9.1  6.3 years
old).
Mean hypoglycemic score pre-ITx
was 5.29  1.51 and was inversely corre-
lated with pre-ITx glycemic control, as
measured by A1C (r  0.370, P 
0.040). A decrease in hypoglycemic score
was observed post-ITx (1.35  1.92, P 
0.001).Similarly,therewasareductionin
the proportion of patients with hypogly-
cemia unawareness (pre- vs. post-ITx: 87
vs. 13%, P  0.001) and an increase in
glycemic threshold that resulted in symp-
toms (pre- vs. post-ITx: 41.4  17.6 vs.
58.4  10.3 mg/dl, P  0.001). Results
were sustained even after the patient’s
stratiﬁcation based on islet function (pre-
vs. post-ITx off insulin: 5.63  2.00 vs.
no hypoglycemia reported; graft dysfunc-
tion: 5.31  1.49 vs. 1.15  1.63, P 
0.001; and graft failure: 5.00  1.16 vs.
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ever, an increase in post-ITx hypoglyce-
mic score was observed as patients lost
graft function (P  0.007).
A1C improved in off-insulin (6.8 
0.8 vs. 6.0  0.6, P  0.038) and graft
dysfunction(7.51.2vs.6.70.5,P
0.022) subjects, and no further deteriora-
tion was observed after graft failure
(7.0  0.9 vs. 7.4  0.9, P  0.318),
suggestingthatrecoveryofawarenesswas
a consequence of glycemic stability rather
than metabolic deterioration associated
with a less strict therapy.
Additionally, a lower hypoglycemic
score correlated with better -cell func-
tion (r  0.440, P  0.013, and r 
0.496, P  0.001, post-ITx fasting and
stimulated C-peptide, respectively). Fol-
low-up was similar for all groups (49.3 
20.3 vs. 42.7  22.2 vs. 51.5  21.9
months, P  0.602), and no clinical or
laboratory factors were associated with
hypoglycemia unawareness post-ITx, in-
cludingdiabetesdurationandpresenceof
neuropathy (data not shown).
CONCLUSIONS — In this sample of
unstable type 1 diabetic patients, glucose
stabilization after ITx was associated with
restoration of hypoglycemia awareness.
Interestingly, improvements in hypogly-
cemia awareness were sustained even af-
ter graft failure.
Restoration of hypoglycemia aware-
ness can be achieved with medical treat-
ment or pancreatic transplantation.
Medical treatment is driven by hypogly-
cemiaavoidancebutcanleadtometabolic
deterioration if it is necessary to lower the
insulin dose (5). Pancreatic transplanta-
tion reestablishes normal glucose ho-
meostasis (6), but the surgical risks are a
limitation.
No hypoglycemia has been reported
after ITx in patients achieving insulin in-
dependence (1). After developing graft
dysfunction and reintroducing exoge-
nousinsulin,hypoglycemicepisodesmay
resume, although with a much lower fre-
quency than pre-ITx. Based on these ob-
servations, it is conceivable that ITx
recipients regain adrenergic symptoms. In-
deed, an improvement in hypoglycemia
awareness after ITx was suggested by a
small-sample short-term clamp study (2),
although the literature is not consistent (3).
To the best of our knowledge, this is
the ﬁrst report of restoration of hypogly-
cemiaawarenessafterITx,whichincludes
more than a few patients and has a longer
follow-up,andwehavedemonstratedsta-
tistically signiﬁcant beneﬁts even after
graft failure No hypoglycemia was re-
ported by off-insulin subjects; the recov-
ery of hypoglycemia awareness found in
patients with graft dysfunction was pre-
dictable and was probably related to tight
glycemic control due to ITx and preven-
tion of hypoglycemia. In graft failure pa-
tients, avoidance of hypoglycemia during
the early post-ITx period possibly led to
increased awareness, which was main-
tained after loss of graft function. Hypo-
glycemia unawareness relapse was
observed in this group, even though the
score remained in the normal range.
The retrospective design of this study
did not allow for more frequent evalua-
tions and better description of patient
symptoms that would have enhanced the
study. Despite this limitation we were
abletoidentifytherestorationofhypogly-
cemia awareness.
In conclusion, the stable metabolic
control achieved by ITx restores hypogly-
cemiaawarenessintype1diabeticsubjects.
These beneﬁts were accomplished without
metabolic deterioration, independent of di-
abetes duration or presence of autonomic
neuropathy, and persisted beyond the du-
ration of islet graft function.
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Figure1—Hypoglycemicscore(Clarkescore;4)(A)andproportionofsubjectswithhypoglycemiaunawareness(hypoglycemicscore4)(B)pre-
andpost-ITx,accordingtoisletfunction.P0.007forcomparisonofposttransplanthypoglycemicscorebetweenoff-insulinandgraftfailuregroups.
*P value is not applicable, since no hypoglycemia was reported posttransplant.
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